MENU
+Compare
AKRO
Stock ticker: NASDAQ
AS OF
Oct 14 closing price
Price
$53.81
Change
+$0.15 (+0.28%)
Capitalization
4.31B

AKRO Akero Therapeutics Forecast, Technical & Fundamental Analysis

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs... Show more

AKRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for AKRO with price predictions
Oct 08, 2025

AKRO saw its Stochastic Oscillator peaks and leaves the overbought zone

The Stochastic Oscillator for AKRO moved out of overbought territory on October 02, 2025. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 54 similar instances where the indicator exited the overbought zone. In of the 54 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 06, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on AKRO as a result. In of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

AKRO moved below its 50-day moving average on October 01, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AKRO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

AKRO broke above its upper Bollinger Band on September 23, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for AKRO entered a downward trend on September 24, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where AKRO's RSI Indicator exited the oversold zone, of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for AKRO just turned positive on September 18, 2025. Looking at past instances where AKRO's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AKRO advanced for three days, in of 306 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.205) is normal, around the industry mean (23.456). P/E Ratio (0.000) is within average values for comparable stocks, (54.341). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.164). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (347.799).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AKRO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AKRO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
AKRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

AKRO is expected to report earnings to rise 8.28% to -93 cents per share on November 12

Akero Therapeutics AKRO Stock Earnings Reports
Q3'25
Est.
$-0.93
Q2'25
Beat
by $0.04
Q1'25
Beat
by $0.11
Q4'24
Beat
by $0.17
Q3'24
Missed
by $0.17
The last earnings report on August 08 showed earnings per share of -86 cents, beating the estimate of -89 cents. With 2.23M shares outstanding, the current market capitalization sits at 4.31B.
A.I. Advisor
published General Information

General Information

a biotechnology company, which specializes in transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases.

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
601 Gateway Boulevard
Phone
+1 650 487-6488
Employees
56
Web
https://www.akerotx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RPMNX17.260.22
+1.29%
Reinhart Mid Cap PMV Institutional
HSPCX17.030.09
+0.53%
Emerald Growth C
JIGCX54.310.26
+0.48%
Janus Henderson Overseas C
WFSTX12.52-0.08
-0.63%
Allspring Innovation Fund - Class A
TRZBX219.76-2.08
-0.94%
T. Rowe Price Blue Chip Growth Z

AKRO and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, AKRO has been loosely correlated with ETNB. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if AKRO jumps, then ETNB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKRO
1D Price
Change %
AKRO100%
+0.28%
ETNB - AKRO
53%
Loosely correlated
-0.07%
SLS - AKRO
42%
Loosely correlated
+2.50%
VTYX - AKRO
38%
Loosely correlated
-1.62%
MDGL - AKRO
37%
Loosely correlated
+2.19%
IDYA - AKRO
35%
Loosely correlated
+1.12%
More